Back to Agenda
Session 1 continued: Adverse Reaction Reporting and Analysis, EudraVigilance System Changes to Come
Speaker(s)
Georgy Genov, MD
Head of Pharmacovigilance Office, European Medicines Agency, Netherlands
Signal Management at the EMA, Planned Revision of GVP Module IX (Signal Management) and the Scientific Guideline on Signal Detection
David John Lewis, PHD
Former Head QPPV PRRC Office, Patient Safety & Pharmacovigilance, Novartis Pharma Gmbh, Switzerland
Industry Readiness for the New EudraVigilance
Have an account?